Danish Pharmacovigilance Update, 18 August 2011

09 September 2011

In this issue of Danish Pharmacovigilance Update:

  • Vimpat® 15mg/ml syrup (lacosamide) for treatment of epilepsy recalled due to a quality defect
  • Nplate® (romiplostim) may increase the risk of disease progression in patients with myelodysplastic syndrome (MDS)
  • Sprycel® (dasatinib) for treatment of certain types of leukaemia and risk of precapillary pulmonary arterial hypertension (PAH)
  • MabThera® (rituximab) and risk of fatal infusion-related reactions in patients with rheumatoid arthritis
  • Antipsychotic treatment during pregnancy and risk of withdrawal symptoms and extrapyramidal effects in newborns
  • Hydrochlorothiazide is not recommended during breast-feeding – but no evidence suggests a contraindication
  • Multaq® (dronedarone) study stopped due to cardiovascular adverse reactions
  • Concomitant treatment with fusidic acid and statins cause increased risk of rhabdomyolysis
  • The European Medicines Agency recommends limited use of anti-diabetic medicine with pioglitazone (Actos®)
  • Limited availability of Thyrogen® (thyrotropin alfa) expected to continue in 2011 and 2012
  • The European Medicines Agency still concludes that the benefits of the smoking cessation product Champix® (varenicline) outweigh the risks.
  • Beta-blockers for ophthalmic use – harmonisation of product information with regard to the risk of systemic adverse reactions
  • Update on Pandemrix® and narcolepsy
  • The benefit-risk balance of reboxetine (Edronax®) remains positive
  • Magistrally manufactured testosterone 10 % for topical use – risk of virilisation in children after exposure
  • Long-term use of bisphosphonates and a risk of atypical fractures

Download the newsletter in the box to the right.

Did you get answers to your questions?

Please tell us how we can improve our website? Please note that we do not answer questions asked via this feature.